Browsing "1. Journal Papers" by Author : 4229

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:
  • Sort by:
  • In order:
  • Results/Page
  • Authors/Record:

Showing results 241 to 300 of 432

This table browses all dspace content
Issue DateTitleJournal Title
2021Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma ANNALS OF ONCOLOGY
2023Monitoring the Outcomes of Systemic Chemotherapy Including Immune Checkpoint Inhibitor for HER2-Positive Metastatic Gastric Cancer by Liquid Biopsy YONSEI MEDICAL JOURNAL
2001Monthly 5-days 5-fluorouracil and low-dose leucovorin for adjuvant chemotherapy in colon cancerCANCER LETTERS
2022MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+gastric or gastroesophageal junction adenocarcinoma-Trial in progressJOURNAL OF CLINICAL ONCOLOGY
2007Multi-institutional phase II study of S-1 monotherapy in advanced gastric cancer with pharmacokinetic and pharmacogenomic evaluations ONCOLOGIST
2022Multicenter phase Ib/II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: Updated HER-RAM study with biomarker analysisJOURNAL OF CLINICAL ONCOLOGY
2008Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancerBREAST CANCER RESEARCH AND TREATMENT
2005Neoadjuvant chemotherapy with infusional 5-fluorouracil, adriamycin and cyclophosphamide (iFAC) in locally advanced breast cancer: an early response predicts good prognosis ANNALS OF ONCOLOGY
2016Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus ONCOTARGET
2017Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trialLANCET
2021Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab GASTRIC CANCER
2022Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trialLANCET ONCOLOGY
2007Novel and simple transformation algorithm for combining microarray data sets BMC BIOINFORMATICS
2008Novel biomarker candidates for gastric cancerONCOLOGY REPORTS
2023Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer SCIENTIFIC REPORTS
2009Oncogenic pathway combinations predict clinical prognosis in gastric cancer PLOS GENETICS
2024Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer StudyJOURNAL OF CLINICAL ONCOLOGY
2020Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768IMOLECULAR CANCER THERAPEUTICS
2023Outcomes of an Acute Palliative Care Unit at a Comprehensive Cancer Center in Korea PALLIATIVE MEDICINE REPORTS
2010Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial designCANCER CHEMOTHERAPY AND PHARMACOLOGY
1996Overexpression of c-ErbB-2 Protein in Gastric Cancer by Immunohistochemical StainONCOLOGY
2012Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy PLOS ONE
1996P-glycoprotein as an intermediate end point of drug resistance to neoadjuvant chemotherapy in locally advanced gastric cancer YONSEI MEDICAL JOURNAL
1997P-glycoprotein: The intermediate end point of drug response to induction chemotherapy in locally advanced breast cancerBREAST CANCER RESEARCH AND TREATMENT
2021p16 methylation is a potential predictive marker for abemaciclib sensitivity in gastric cancerBIOCHEMICAL PHARMACOLOGY
1998p53 유전자 변형이 발생한 위암세포주에서 유전자이상 교정에 의한 항암제 감수성 변화 Journal of the Korean Cancer Association (대한암학회지)
2010Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistanceCANCER CHEMOTHERAPY AND PHARMACOLOGY
2022PD-L1 expression and overall survival in Asian and western patients with gastric cancerFUTURE ONCOLOGY
2020Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 StudiesJOURNAL OF THORACIC ONCOLOGY
2019Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study Gastric Cancer
2016Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trialLANCET ONCOLOGY
2018Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012 CANCER SCIENCE
2023Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062 JAPANESE JOURNAL OF CLINICAL ONCOLOGY
2023Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trialLANCET
2018Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trialLANCET
2022Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1-positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trialJOURNAL OF CLINICAL ONCOLOGY
2008Pemetrexed and cisplatin in patients with advanced gastric cancer: a Korean cancer study group multicenter phase II study.CANCER CHEMOTHERAPY AND PHARMACOLOGY
1995Perioperative blood transfusions and prognosis in patients with curatively resected locally advanced gatric cancerONCOLOGY
2021Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations INVESTIGATIONAL NEW DRUGS
2008Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancerRADIOTHERAPY AND ONCOLOGY
2014Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxaneCANCER CHEMOTHERAPY AND PHARMACOLOGY
2008Phase II study of combination chemotherapy of 5-fluorouracil, low-dose leucovorin, and oxaliplatin (FLOX regimen) in pretreated advanced gastric cancer ANNALS OF ONCOLOGY
2010Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancerRADIOTHERAPY AND ONCOLOGY
2011Phase II study of sunitinib as second-line treatment for advanced gastric cancer INVESTIGATIONAL NEW DRUGS
2019Phase II trial of preoperative sequential chemotherapy followed by chemoradiotherapy for high-risk gastric cancerRADIOTHERAPY AND ONCOLOGY
2008Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up. ANNALS OF ONCOLOGY
1998Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patientsBREAST CANCER RESEARCH AND TREATMENT
2015PINCH-2 presents functional copy number variation and suppresses migration of colon cancer cells by paracrine activityINTERNATIONAL JOURNAL OF CANCER
2009Postoperative adjuvant chemotherapy of gastric cancer: scrutiny into the clinical evidence based on quality assessment of medical literature of randomized controlled trialsCANCER CHEMOTHERAPY AND PHARMACOLOGY
2009Prediction of high-risk patients by genome-wide copy number alterations from remaining cancer after neoadjuvant chemotherapy and surgery.INTERNATIONAL JOURNAL OF ONCOLOGY
2013Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer BMC CANCER
2009Prediction of recurrence of early gastric cancer after curative resectionANNALS OF SURGICAL ONCOLOGY
2009Prediction of S-1-induced anemiaGASTRIC CANCER
2011Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancerANTI-CANCER DRUGS
2011Prevalence and associated factors of psychological distress among Korean cancer patientsGENERAL HOSPITAL PSYCHIATRY
2017Prevalence and prognostic implications of psychological distress in patients with gastric cancer BMC CANCER
1995Primary lymphoma of thyroid YONSEI MEDICAL JOURNAL
2023Prior antibiotic administration disrupts anti-PD-1 responses in advanced gastric cancer by altering the gut microbiome and systemic immune response CELL REPORTS MEDICINE
2022Probe-Based Confocal Laser Endomicroscopy versus White-Light Endoscopy with Narrow-Band Imaging for Predicting and Collecting Residual Cancer Tissue in Patients with Gastric Cancer Receiving Chemotherapy CANCERS
2009Prognosis of pN3 stage gastric cancer CANCER RESEARCH AND TREATMENT

Browse

Links